USFDA excludes Ceftriazone Sodium from import alert: Wockhardt
New Delhi : Drug firm Wockhardt said the US health regulator has excluded Ceftriazone Sodium from import alert issued earlier against its active pharmaceutical ingredient manufacturing facility at Ankleshwar.
The United States Food and Drug Administration (USFDA) on September 30, 2016 has posted on its website an update on the Import Alert 66-40 "regarding company's API Unit at Ankleshwar" and excluded Ceftriazone Sodium from it, Wockhardt said in a filing to BSE.
"This will enable the company to manufacture and sell Ceftriazone API and formulation to US market," it added.
Shares of Wockhardt closed at Rs 894.45 per scrip on BSE, up 1.86 per cent from its previous close.